Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints
Viridian Therapeutics will be reporting data from a second Phase III trial of veligrotug before the end of 2024.
EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children
Incendia enrols first subject in Phase Ic advanced solid tumour trial
EASD 2024: Survodutide shows promise in overweight, obesity and MASH
Basking Biosciences doses first subject in Phase II acute ischaemic stroke trial
Johnson & Johnson reports data from Phase II NSCLC treatment trial
Immunis receives FDA clearance for Phase II sarcopenic obesity therapy trial
EASD 2024: Bayer’s Kerendia continues to impress with pooled analysis
Analysis
View More
Themes
View MoreAstraZeneca eyes up transition to eco-friendly inhaler propellant
Results from AstraZeneca’s completed clinical studies will be shared with regulatory authorities by the end of this year.
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
As mpox spreads, ‘national governments have a moral responsibility to help’
Ultromics’s EchoGo misses primary endpoint in heart disease trial
NHS report touts effectiveness of Skin Analytics’ DERM AI melanoma tool
Spectral AI hits enrollment goal at burn centres for AI-powered assessment tech